Genetic analysis of early- versus late-stage ovarian tumors

Cancer Research

Volumn 61, Issue 15, 2001, Pages 5895-5904

  Shridhar, Viji ^a   Pandita, Ajay ^a   Avula, Rajeswari ^a   Staub, Julie ^a   Calhoun, Eric ^a   Roche, Patrick ^a   James, C David ^a   Couch, Fergus J ^a   Smith, David I ^a   Iturria, Steve ^a   Kalli, Kimberly ^a   Keeney, Gary ^a   Cliby, William ^a   Hartmann, Lynn C ^a   Lee, John ^b   Morrissey, Mike ^b   Sen, Ami ^b   Lillie, Jim ^b   Lu, Karen ^c   Schmandt, Rosemarie ^c   Mills, Gordon B ^c   Bast, Robert ^c   more..

^a MAYO CLINIC   (United States)

^b Millennium Predictive Medicine Inc   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA;

ADVANCED CANCER; ARTICLE; CANCER MORTALITY; CANCER STAGING; CARCINOGENESIS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA MICROARRAY; EXPRESSED SEQUENCE TAG; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TECHNIQUE; UNITED STATES;

DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; NEOPLASM STAGING; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 0035421991     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Cancer statistics, 1999
2. Prognostic factors in ovarian cancer
3. Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer
4. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors
5. BRCA1-associated growth arrest is RB-dependent
6. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas
7. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: Correlation with disease characteristics
8. Prognostic significance of ras/p21 alterations in human ovarian cancer
9. C-myc mRNA expression in epithelial ovarian carcinomas in relation to estrogen receptor status, metastatic spread, survival time. FIGO stage, and histologic grade and type
10. Interaction between the adhesion receptor, CD44, and the oncogene product, p185HER2, promotes human ovarian tumor cell activation
11. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray
12. Classification of human ovarian tumors using multivariate data analysis of polypeptide expression patterns
13. Quantitative monitoring of gene expression patterns with a complementary DNA microarray
14. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors
15. Biological characterization of human epithelial ovarian carcinoma cells in primary culture: The insulin-like growth factor system
16. Experimental mode systems of ovarian cancer: Applications to the design and evaluation of new treatment approaches
17. Definition of a continuous human cell line derived from neuroblastoma
18. Cluster analysis and display of genome-wide expression patterns
19. Localization of human cadherin genes to chromosome regions exhibiting cancer-related loss of heterozygosity
20. Expression of E-cadherin and N-cadherin in surface epithelial-stromal tumors of the ovary distinguishes mucinous from serous and endometrioid tumors
21. Differential regulation of the human nidogen gene promoter region by a novel cell-type-specific silencer element
22. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma
23. The matrix metalloprotease pump-1 (MMP-7. Matrilysin): A candidate marker/target for ovarian cancer detection and treatment
24. Increased matrix metalloproteinase-9 activity in human ovarian cancer cells cultured with conditioned medium from human peritoneal tissue
25. Coding sequence and growth regulation of the human vimentin gene
26. Mapping the gene for palmoplantar hyperkeratosis (thylosis) to chromosome 17 in the 17q12-q24 region
27. Localization of the gene for human simple epithelial keratin 18 to chromosome 12 using polymerase chain reaction
28. Isolation, sequence and expression of the gene encoding human keratin 13
29. Cyclins D1 and D2 are differentially expressed in human B-lymphoid cell lines
30. Perturbation of cell cycle regulators in human cancer
31. Analysis of the domain requirement in Gas1 growth suppressing activity
32. Oncogenic capacity of the E2F1 gene
33. Cyclin E2, a novel G1 cyclin that binds Cdk2 and is aberrantly expressed in human cancers
34. Expression and prognostic significance of proliferating cell nuclear antigen and Ki-67 in malignant ovarian germ cell tumors
35. Human E2F5 gene is oncogenic in primary rodent cells and is amplified in human breast tumors
36. Mucin gene expression in ovarian cancers
37. Serum ceruloplasmin as a diagnostic marker of cancer
38. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer
39. Comparative hybridization of an array of 21, 500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas
40. In vitro growth inhibition of ovarian cancer cells by decorin: Synergism of action between decorin and carboplatin
41. The plasminogen-activation system in ovarian tumors
42. Induction of matrix metalloprotease-7 is common in mucinous ovarian tumors including early stage disease
43. 3β-hydroxysteroid dehydrogenase activity in tissues of the human fetus determined with 5α-androstane-3β, 17β-diol and dehydroepiandrosterone as substrates
44. Retinoic acids up-regulate steroidogenic acute regulatory protein gene
45. Smad3 is involved in the intracellular signaling pathways that mediate the inhibitory effects of transforming growth factor-β on StAR expression
46. Amphiregulin antisense oligonucleotide inhibits the growth of T3M4 human pancreatic cancer cells and sensitizes the cells to EGF receptor-targeted therapy
47. Coexpression of rat glutathione S-transferase A3 and human cytidine deaminase by a bicistronic retroviral vector confers in vitro resistance to nitrogen mustards and 1-β-d-arabinofuranosylcytosine in murine fibroblasts
48. Organization and parent-of-origin-specific methylation of imprinted Peg3 gene on mouse proximal chromosome 7
49. Collagenase-3 (MMP-13) and integral membrane protein 2a (Itm2a) are marker genes of chondrogenic/osteoblastic cells in bone formation: Sequential temporal, and spatial expression of Itm2a, alkaline phosphatase, MMP-13, and osteocalcin in the mouse
50. Decorin is a biological ligand for the epidermal growth factor receptor
51. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5- methylisoxazole-4-carboxamide
52. Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis
53. Secreted frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells
54. Cyclin D1 overexpression and p53 mutation status in epithelial ovarian cancer
55. Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours
56. Structure and chromosomal localization of the human prostasin (PRSS8) gene
57. Cytokeratins 20 and 7 in the differential diagnosis of metastatic carcinoma in cytologic specimens
58. Allelic imbalance in chromosome band 18q21 and SMAD4 mutations in ovarian cancers
59. Loss of heterozygosity on chromosome 5 in sporadic ovarian carcinoma is a late event and is not associated with mutations in APC at 5q21-22
60. Loss of heterozygosity at the α-inhibin locus on chromosome 2q is not a feature of human granulosa cell tumors
61. Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells
62. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002)
63. c-myc amplification in ovarian cancer
64. Association of Ki-ras with amplified DNA sequences, detected in human ovarian carcinomas by a modified in-gel renaturation assay
65. Genetic abnormalities detected by comparative genomic hybridization in a human endometriosis-derived cell line
66. DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours
67. Tissue microarrays for gene amplification surveys in many different tumor types
68. Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells
69. Human chromatid cohesin component hRad21 Is phosphorylated in M phase and associated with metaphase centromeres
70. Exclusion of muscle specific actinin-associated LIM protein (ALP) gene from 4q35 facioscapulohumeral muscular dystrophy (FSHD) candidate genes
71. Hevin, an antiadhesive extracellular matrix protein, is down-regulated in metastatic prostate adenocarcinoma
72. DNA methylation: Past, present and future directions
73. Alterations in DNA methylation are early, but not initial, events in ovarian tumorigenesis
74. Progressive increases in the methylation status and heterochromatinization of the myoD CpG island during oncogenic transformation
75. Detection of cellular heterogeneity by DNA ploidy, 17 chromosome, and p53 gene in primary carcinoma and metastasis in a case of ovarian cancer
76. Role of protooncogene activation in carcinogenesis
77. Heterogeneous protooncogene amplification correlates with tumor progression and presence of metastases in gastric cancer patients